# Clinical Management of Intraductal Carcinoma of the Prostate

## TL;DR

This review discusses intraductal prostate cancer, a unique type with distinct features that affect treatment decisions and patient outcomes.

## Contribution

The paper provides a comprehensive review of IDC-P's clinical significance and highlights the need for tailored treatment strategies.

## Key findings

- IDC-P is associated with aggressive disease and poor outcomes across prostate cancer stages.
- Standardized management guidelines for IDC-P are currently lacking.
- Adjuvant and neoadjuvant therapies may improve outcomes for specific IDC-P patient cohorts.

## Abstract

Prostate cancer is a common and challenging disease among men, prompting researchers to explore new ways to understand and manage it effectively. In this review, we focus on a specific type of prostate cancer called intraductal carcinoma (IDC-P), which has unique characteristics and implications for patient care. We aim to clarify the clinical significance of IDC-P and its impact on treatment decisions. Pathological features and molecular aspects offer insights into better risk stratification and treatment approaches for patients with IDC-P.

Intraductal carcinoma of the prostate (IDC-P) has emerged as a distinct entity with significant clinical implications in prostate cancer (PCa) management. Despite historically being considered an extension of invasive PCa, IDC-P shows unique biological characteristics that challenge traditional diagnostic and therapeutic settings. This review explores the clinical management of IDC-P. While the diagnosis of IDC-P relies on specific morphological criteria, its detection remains challenging due to inter-observer variability. Emerging evidence underscores the association of IDC-P with aggressive disease and poor clinical outcomes across various PCa stages. However, standardized management guidelines for IDC-P are lacking. Recent studies suggest considering adjuvant and neoadjuvant therapies in specific patient cohorts to improve outcomes and tailor treatment strategies based on the IDC-P status. However, the current level of evidence regarding this is low. Moving forward, a deeper understanding of the pathogenesis of IDC-P and its interaction with conventional PCa subtypes is crucial for refining risk stratification and therapeutic interventions.